Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

CD56brightCD16- NATURAL KILLER CELLS ARE IN HIGHER COUNTS IN THE UMBILICAL CORD BLOOD THAN IN THE PERIPHERAL BLOOD

View ORCID ProfileVinicius Campos de Molla, Míriam Cristina Rodrigues Barbosa, Alfredo Mendrone Junior, Matheus Vescovi Gonçalves, Eliza Kimura, Fabio Guirao, Mihoko Yamamoto, Celso Arrais-Rodrigues
doi: https://doi.org/10.1101/2021.06.09.21258083
Vinicius Campos de Molla
1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, São Paulo, Brazil
2Centro de Oncologia. Hospital Sírio Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vinicius Campos de Molla
  • For correspondence: vinciuscamposdemolla{at}gmail.com
Míriam Cristina Rodrigues Barbosa
1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfredo Mendrone Junior
2Centro de Oncologia. Hospital Sírio Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matheus Vescovi Gonçalves
1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliza Kimura
1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabio Guirao
1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mihoko Yamamoto
1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celso Arrais-Rodrigues
1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, São Paulo, Brazil
2Centro de Oncologia. Hospital Sírio Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Umbilical cord blood (UCB) is an alternative source for hematopoietic stem cells allogeneic hematopoietic stem cell transplantation in the absence of compatible donor. UCB transplantation has a lower incidence of chronic graft versus host disease (GvHD) but is associated with slower engraftment and slower immune reconstitution as compared to other sources. Dendritic cells (DC) and Natural Killer cells (NK) play a central role in the development of GVHD, the graft versus leukemia (GvL) effect, and in the control of infectious complications. We quantified by multiparametric flow cytometry monocytes, lymphocytes, NK cells, and DC, including their subsets, in UCB samples from 54 healthy newborns and peripheral blood (PB) from 25 healthy adult volunteers. In the UCB samples, there were higher counts of CD56brightCD16-NK cells (median 0.024×109/L), as compared to the PB samples (0.012×109/L, P<0.0001), CD56dimCD16bright NK cells (median 0.446×109/L vs. 0.259×109/L for PB samples, P= 0.001), and plasmacytoid dendritic cells (pDC, median 0.008×109/L for UCB samples vs. 0.006×109/L for PB samples, P= 0.03). Moreover, non-classical monocytes counts were lower in UCB than in PB (median 0.024×109/L vs. 0.051 x109/L, respectively, P< 0.0001). In conclusion, there were higher counts of NK cells and pDC, and lower counts of non-classical monocytes in UCB than in PB from healthy individuals. These findings might explain the lower incidence and severity of chronic GVHD although maintaining the GVL effect in UCB transplants recipients as compared to other stem cell sources.

Highlights

  • CD56brightCD16- NK cells are more frequent in UCB than in PB.

  • Plasmacytoid dendritic cells are more frequent in UCB than in PB.

  • Non-classical monocytes are more frequent in PB than in UCB.

INTRODUCTION

In the last few years, allogeneic hematopoietic stem cell transplantation (HSCT) has improved clinical outcomes, with less transplant-related mortality (TRM) and better overall survival (OS) (1). Despite the advance in the knowledge of immune reconstitution in HSCT, there are still gaps in this field, such as the mechanisms of immunotolerance, graft-versus-host-disease (GvHD) or graft-versus-leukemia (GvL) effect (2).

Umbilical cord blood (UCB) transplant was performed for the first time in 1988 (3). UCB transplant is associated with delayed engraftment, increased risk of infections, greater engraftment failure, and worse TRM, as compared to bone marrow (BM) and peripheral blood (PB) sources (4). However, UCB transplant usually causes less acute GvHD (aGvHD) and chronic GvHD (cGvHD) with similar rates of leukemia-free survival (5). This could be explained by distinctive patterns of immune reconstitution according to graft source (6), regardless of the conditioning regimen (7).

Dendritic cells (DC) are antigen-presenting cells, making the connection between innate and adaptive immunity (8), and also coordinating the immune system through activation and stimulation of T and B cells, tolerance by removal of self-reactive T cells (9) and linkage with regulatory T cells (10). So, DC play a key role in immune system control. In the PB, DC are present in two subsets: myeloid (or conventional) DC (mDC) and plasmacytoid DC (pDC). The pDC (CD123+CD11c) produce interferon (IFN) I and are implicated in viral immune response, immune tolerance, and memory. At the same time, mDC (CD123-CD11c+) are responsible for a proinflammatory effect. Each DC subset is flexible in vivo and its responses vary according to factors such as their activation state, the nature of the stimulus received, and the inflammatory microenvironment (11). In the immune recovery after HSCT, DC play a relevant role in aGvHD, cGvHD, GVL and host response to infections (12), and a poor DC reconstitution is associated with increased risk of relapse and poor survival (13,14).

NKT cells (NKT) are T cells that express NK receptors, including NK 1.1 (CD161c) and semi-invariant CD1d-restricted αβ TCRs. There are two types of NKT: type I NKT (or iNKT) that express Vα24-Jα18, and type II NKT that express other TCR different than Vα24-Jα18 (15).

Natural killer cells (NK) are components of the innate immune system, eliminating tumor and infected cells, promoting cellular lysis in the absence of the HLA class I receptor. NK cells are categorized as CD56dimCD16bright (90% of NK in PB) with predominant cytotoxic effect through the release of granzyme B and perforin, and CD56brightCD16-related to INF-γ and tumor necrosis factor α (TNF-α) secretion (16). NK are the first cells to recover after HSCT and strongly contribute to the GvL effect, possibly due to killer-cell immunoglobulin-like receptor (KIR) mismatch (17). It has been shown that low counts of NK CD56brightCD16-after HSCT are associated with a lower survival rate (18), and KIR mismatches improve survival (19).

To better understand the mechanisms involved in different outcomes in HSCT using UCB or PB, we compared the composition of immune-related cells in these two HSC sources (monocytes, B lymphocytes, T cells, NK cells, and DC and their subsets) in samples from UCB and PB.

MATERIALS AND METHODS

Population and design

This was an analytical case-control study. Samples from 54 UCB and 25 PB were collected between September 2015 and July 2017. UCB samples from healthy newborns, with a minimum gestational age of 35 weeks, were collected at the Cellular Therapy Center of Hospital Sírio Libanês (before freezing). UCB from neonates with any antenatal risk factors were excluded. PB samples were collected from healthy adult blood donors at Hospital São Paulo / UNIFESP Blood Center. Blood donors and pregnant women who agreed to donate UCB (both ≥ 18 years old), without any documented chronic illness or infectious disease entered the study. Blood donor volunteers with blood transfusion in the last 3 months were excluded.

The study was approved by the local ethics committee of the participating centers and all volunteers (blood donors and mothers) gave their informed consent before entering the study, in accordance with the Declaration of Helsinki.

Cells Identification and count by Flow Cytometry

Fresh EDTA-anticoagulated PB or UCB samples were processed in up to 24 hours after collection. Total nucleated cells from UCB were quantified by Coulter AcT Diff 2® (Beckman Coulter, Brea, EUA) and PB cells by Cell Dyn Ruby® (Abbott, Illinois, EUA) and erythroblasts were quantified by microscopy to correct the leukocytes count. Leukocytes and subsets were analyzed by flow cytometry.

Cells were stained using an 8-color monoclonal antibodies panel: CD16 FITC / CD56 & CD4 PE / CD11c PerCP Cy5.5 / CD8 & CD19 PC7 / CD123 APC / CD3 & CD14 APC-H7,/ HLA-DR Pac Blue/ CD45 OC-515, by stain-lyse-wash method. The reagents were purchased from: Cytognos, Salamanca (CD16, CD56, CD4, CD45), BDB, San Jose CA(CD11c, CD3, CD14), Immunotech Brea (CD8), Immunotech Marseille (CD19), Biolegend, San Diego (HLA-DR, CD123), Data acquisition (500×103 total events) was performed using FACSCANTOII flow cytometer (BDB-San Jose, CA) and FACsDIVA® software (BDB-San Jose, CA) and Infinicity® software (Cytognos, SL) was used for data analysis. NK cells (CD3-, CD19-, CD14-, and CD56+), were classified as CD56brightCD16- or CD56dimCD16bright. Monocytes (CD45+, CD11c+, and HLA-DR+) were classified as: classic (CD14++CD16-), intermediate (CD14++CD16+) and non-classical (CD14dimCD16++). Dendritic cells (HLA-DR++, CD3-, CD19-, CD14-, and CD56-) were classified as pDC (CD123+/ CD11c-), and mDC (CD123-/ CD11c++).

Statistical Methods

Descriptive statistical analysis was reported by using percentages (categorical variables) and ranges and medians (continuous variables). Comparisons between UCB and PB were performed using the Mann-Whitney test. A P value of <.05 was considered significant. SPSS version 21.0 (SPSS Inc., Chicago, IL) was used for all statistical analyses.

RESULTS

Clinical Characteristics

Seventy-nine samples (54 UCB and 25 PB) were obtained. UCB samples were collected from newborns with a median gestational age of 40 weeks (range: 36 to 43 weeks), and birth weight of 3.263kg (range: 2.530 to 4.005kg). Twenty-nine (54%) newborns were male. Vaginal delivery was more commonly used (74%) than the cesarean section (26%). PB samples donors median age was 33 years old (range 18 to 66 years old), and 15 (60%) were male.

Absolute counts of WBCs and subpopulations

Total white blood cell (WBC) count was higher in UCB than in PB (10.782×109cells/L vs. 6.980×109cells/L, P<0.0001). The total number of cells from most lineages (neutrophils, eosinophils, monocytes, B cells) were higher in UCB, while total T cells, NK cells, and total DCs were similar in both groups (Table 1). Among subpopulations, many differences were noted: non-classical monocytes, double positive CD4+CD8+ T cells and double negative CD4-CD8-T cells were in higher counts in PB than in UCB (0.051×109cells/L vs. 0.024×109cells/L, P<0.0001; 0.005×109cells/L vs. 0.001×109cells/L, P<0.0001; 0.054×109cells/L vs 0.039×109cells/L, P=0.005, respectively). However, pDC were in lower counts in PB than in UCB (0.006×109cells/L vs. 0.008×109cells/L, P=0.03, Table 2). No significant statistical difference was observed in mDC counts between the groups.

Relative frequencies of WBCs and subpopulations

The proportion of B cells and NK cells were higher in UCB samples when compared to PB samples (16% vs. 11%, P<0.0001; 20% vs. 11%, P<0.006, respectively).

In terms of relative frequencies of subpopulations, classical monocytes were the predominant subset being present in a higher count in UCB vs PB (89% vs 77%, P<0.006×109, respectively. Classical monocytes: non-classical monocytes ratio was 28.3 in UCB and 7.0 in PB (P<0.0001).

T cells CD4+ were more prevalent than T cells CD8+ in both PB and UCB (CD4: CD8 ratio 1.8 and 2.3, respectively), while T cells CD8+ were more frequent in PB (31%), rather than UCB (27%, P=0.03).

NK cells CD56dimCD16bright counts were the predominant subset in both samples (96% and 93%, PB and UCB, respectively). The ratio between the subtypes (NK cell CD56dimCD16bright:CD56brightCD16-) was lower in UCB (13.7) vs. PB (24, P=0.03). CD56dimCD16bright proportions of pDC in UCB as compared to PB from normal adults

The mDC were the predominant subtype in both PB and UCB, being 3 times the number of pDC in PB and 1.8 times the number of pDC in UCB. However, there was no difference in mDC absolute counts between the two groups. The pDC proportion was 25% in PB and 36% in UCB (P<0.0001). The mDC:pDC ratio was 3.0 in PB vs.1.8 in UCB (P<0.0001).

The CD4:CD8 ratio was higher in UCB (2.3) than in PB (1.8, P=0.01), and the NK cell CD56dimCD16bright:CD56brightCD16-ratio was lower in UCB (13.7) vs. PB (24, P=0.03). Intermediate monocytes: non-classical monocytes ratio was 28.3 in UCB and 7.0 in PB (P<0.0001). The relative distribution of WBCs and subpopulations are listed in Table 1 and Table 2.

DISCUSSION

In the present study, we compared concentrations (cells per liter) and frequencies (%) of WBCs and subsets in UCB and PB from healthy individuals and observed higher counts and frequencies of CD56brightCD16-NK cells and pDC, and lower counts and frequencies of non-classical monocytes in the UCB. To the best of your knowledge, this is the first study that compared subsets of NK (CD56dimCD16bright, and CD56brightCD16-) between UCB and PB. NK CD56brightCD16-is a more immature NK cell, presenting a more humoral immune response profile, secreting INF-γ, TNF-α, IL-10, IL-13, and granulocyte-macrophage colony-stimulating factor, rather than the direct cytotoxic effect of the NK CD56dimCD16bright. They usually do not present KIR receptors and present higher expressions of the heterodimer CD94/NKG2A (major inhibitor receptor), which confers a lower alloreactivity than their more mature CD56dimCD16bright counterpart (20). Therefore, higher counts and higher frequencies of CD56brightCD16-NK cells and plasmacytoid dendritic cells in UCB as compared to PB could possibly lead to a more tolerogenic profile against host cells in HSCT recipients.

Of interest, monocyte maturation was clearly more evident in PB than in UCB samples. PB showed high proportions of the late phases of monocyte differentiation, like intermediate and non-classical monocytes, which was also observed by some previous studies (21). These populations represent a shift towards higher antigen-presenting activity, and they are considered as monocyte-derived DCs (22), and they are being also related to autoimmune diseases, such as rheumatoid arthritis and Crohn’s disease (23).

We found higher counts of pDC in UCB than in PB, corroborating the findings of Prabhu SB et al (21); pDC produces IFN type I, which is related to antiviral response, immune tolerance, and anti-tumor immunity through secretion of type-I IFN and TNF- α (24). Moreover, our group previously demonstrated that grafts with high pDC content lead to lower aGVHD and lower mortality risk after HSCT (18).

GvHD is a reaction caused in part by donor alloreactive T CD8+ and T cell depletion (in vivo or ex vivo) is a common strategy to mitigate this complication (25,26). Here we demonstrated a higher concentration of T CD8+ in PB when compared with UCB, as has been shown in previous studies (27–29).

All these findings in PB: more mature monocytes, a higher concentration of T CD8+, and lower counts of pDC and CD56brightCD16-NK as compared to UCB might explain the higher incidence of cGvHD when PB is used as stem cell source for HSCT (30). Conversely, the more tolerogenic profile observed in UCB as compared to PB could explain the lower risk of cGvHD with similar relapse rates, as evidence of the sustained GvL effect (5,31,32).

Our study has limitations, such as small sample size, and the use of PB samples without the stimulation of granulocyte colony-stimulating factors, as commonly used for HSCT, which could change the cells counts and frequencies.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Concentrations of lymphocytes, NK cells, dendritic cells, monocytes and respective subsets in PB and UCB samples.

In conclusion, we observed higher counts of CD56brightCD16-NK cells and pDC and lower counts of non-classical monocytes in UCB as compared to PB from healthy individuals. As we propose in Figure 2, our findings demonstrate that UCB cells profile is more tolerogenic than that of PB and this finding might explain the lower incidence and severity of cGVHD in UCB recipients as compared to other stem cell sources, although maintaining the GVL effect. Future research is needed for a better understanding of immune reconstitution in HSCT, and to explain the differences regarding immune reconstitution, GvHD risk, GvL effect and other clinical outcomes in the HSCT among different stem cell sources.

Figure 2.
  • Download figure
  • Open in new tab
Figure 2.

Differences in the profile of cell tolerance and reactivity: the profile of UCB cells is more tolerogenic than that of PB. Abbreviations: mDC myeloid dendritic cells, pDC plasmacytoid dendritic cells, NK 56dim16bright natural killer cells CD56dimCD16bright, TCD8 T cells CD8+, NK 56bright16+ natural killer cells CD56brightCD16-.

Data Availability

The data is available in our database.

FINANCIAL DISCLOSURE STATEMENT

The authors have nothing to disclose.

DECLARATIONS OF INTEREST

There are no conflicts of interest to report.

ACKNOWLEDGMENTS

M.C.R.B. was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, no. 001). V.C.M. was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq process no. 141575/2018-2).

Authorship statement: M.C.R.B., V.C.M, M.V.G., and C.A.R. designed research, performed research, analyzed data, and wrote the paper; V.C.M, M.V.G., and C.A.R. performed statistical analysis; A. M. J. and C. A. A provided cord blood samples, M.C.R.B., M.Y. and M.V.G. performed flow cytometry analysis, critical review, and revised the manuscript. All authors drafted and approved the manuscript and agreed with its submission.

REFERENCES

  1. 1.↵
    Remberger M, Ackefors M, Berglund S, Blennow O, Dahllöf G, Dlugosz A, et al. Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. Biol Blood Marrow Transplant [Internet]. 2011 Nov 1 [cited 2018 Oct 20];17(11):1688–97. Available from: https://www.sciencedirect.com/science/article/pii/S1083879111002072?vi a%3Dihub
    OpenUrl
  2. 2.↵
    van den Brink MRM, Velardi E, Perales M-A. Immune reconstitution following stem cell transplantation. Hematology [Internet]. 2015 Dec 1;2015(1):215–9. Available from: http://www.asheducationbook.org/cgi/doi/10.1182/asheducation-2015.1.215
    OpenUrl
  3. 3.↵
    Gluckman E, Broxmeyer HE, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic Reconstitution in a Patient with Fanconi’s Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling. N Engl J Med [Internet]. 1989 Oct 26;321(17):1174–8. Available from: https://doi.org/10.1056/NEJM198910263211707
    OpenUrl
  4. 4.↵
    Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang M-J, Champlin RE, et al. Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia. N Engl J Med [Internet]. 2004 Nov 25 [cited 2018 Oct 20];351(22):2265–75. Available from: www.nejm.org
    OpenUrl
  5. 5.↵
    Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. N Engl J Med [Internet]. 2004 Nov 25 [cited 2018 Oct 20];351(22):2276–85. Available from: www.nejm.org
    OpenUrl
  6. 6.↵
    Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kao G, et al. Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant [Internet]. 2012 Apr [cited 2018 Oct 20];18(4):565–74. Available from: https://ac.els-cdn.com/S108387911100351X/1-s2.0-S108387911100351X-main.pdf?_tid=a0dc3e79-7ab8-4692-9227-0d6341f72a39&acdnat=1540088113_ffb39ce3d3966ac3de8dbd84094cf5a6.
    OpenUrl
  7. 7.↵
    Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol [Internet]. 2011 Oct;155(2):218–34. Available from: http://doi.wiley.com/10.1111/j.1365-2141.2011.08822.x
    OpenUrl
  8. 8.↵
    Rossi M, Young JW. Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity. J Immunol [Internet]. 2005;175(3):1373–81. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.175.3.1373
    OpenUrl
  9. 9.↵
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature [Internet]. 1998 Mar 19;392(6673):245–52. Available from: http://www.nature.com/articles/32588
    OpenUrl
  10. 10.↵
    Darrasse-Jèze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao K, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med [Internet]. 2009 Aug 31 [cited 2018 Oct 21];206(9):1853–62. Available from: www.jem.org/cgi/doi/10.1084/jem.20090746
    OpenUrl
  11. 11.↵
    Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology [Internet]. 2013 Sep;140(1):22–30. Available from: http://doi.wiley.com/10.1111/imm.12117
    OpenUrl
  12. 12.↵
    Lau J, Sartor M, Bradstock KF, Vuckovic S, Munster DJ, Hart DNJ. Activated Circulating Dendritic Cells After Hematopoietic Stem Cell Transplantation Predict Acute Graft-Versus-Host Disease. Transplantation [Internet]. 2007 Apr [cited 2018 Oct 9];83(7):839–46. Available from: https://insights.ovid.com/crossref?an=00007890-200704150-00002
    OpenUrl
  13. 13.↵
    Waller EK, Logan BR, Harris WAC, Devine SM, Porter DL, Mineishi S, et al. Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. J Clin Oncol [Internet]. 2014 Aug 1 [cited 2018 Oct 21];32(22):2365–72. Available from: http://ascopubs.org/doi/10.1200/JCO.2013.54.4577
    OpenUrl
  14. 14.↵
    Gonçalves MV, Yamamoto M, Kimura EYS, Colturato VAR, de Souza MP, Mauad M, et al. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant [Internet]. 2015;21(7):1223–9. Available from: http://dx.doi.org/10.1016/j.bbmt.2015.03.010
    OpenUrl
  15. 15.↵
    Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res [Internet]. 2008;101(08):277–348. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0065230X0800408z
    OpenUrl
  16. 16.↵
    Caligiuri MA. Human natural killer cells. Blood [Internet]. 2008 Aug 1;112(3):461–9. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2007-09-077438
    OpenUrl
  17. 17.↵
    Ruggeri L, Capanni M, Mancusi A, Perruccio K, Burchielli E, Martelli MF, et al. Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation. Blood [Internet]. 1999 Jul 1;94(1):333 LP-339. Available from: http://www.bloodjournal.org/content/94/1/333.abstract
    OpenUrl
  18. 18.↵
    1. Vescovi Gonçalves M
    Gonçalves MV, Yamamoto M, Kimura EYS, Renzi Colturato VA, Ikoma MV, Mauad M, et al. Low Counts Of Natural Killer Cells CD56 bright CD16 negative After Engraftment Are Associated With Worse Survival In Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Vescovi Gonçalves M, editor. Blood [Internet]. 2013 Nov 15;122(21):4625 LP-4625. Available from: http://www.bloodjournal.org/content/122/21/4625.abstract
    OpenUrl
  19. 19.↵
    Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socié G, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia [Internet]. 2009 Mar 8 [cited 2018 Oct 21];23(3):492–500. Available from: http://www.nature.com/articles/leu2008365
    OpenUrl
  20. 20.↵
    Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56 bright natural killer (NK) cells: an important NK cell subset. Immunology [Internet]. 2009 Apr;126(4):458–65. Available from: http://doi.wiley.com/10.1111/j.1365-2567.2008.03027.x
    OpenUrl
  21. 21.↵
    1. Yu XG, editor
    Prabhu SB, Rathore DK, Nair D, Chaudhary A, Raza S, Kanodia P, et al. Comparison of Human Neonatal and Adult Blood Leukocyte Subset Composition Phenotypes. Yu XG, editor. PLoS One [Internet]. 2016 Sep 9;11(9):e0162242. Available from: https://dx.plos.org/10.1371/journal.pone.0162242
    OpenUrl
  22. 22.↵
    Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al. Phenotype, function, and differentiation potential of human monocyte subsets. PLoS One [Internet]. 2017 Apr 26;12(4):e0176460. Available from: https://doi.org/10.1371/journal.pone.0176460
    OpenUrl
  23. 23.↵
    Yang J, Zhang L, Yu C, Yang X-F, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res [Internet]. 2014 Jan;2(1):1. Available from: https://doi.org/10.1186/2050-7771-2-1
    OpenUrl
  24. 24.↵
    Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol. 2010;40(10):2667–76.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood [Internet]. 2005 Nov 1;106(9):3322 LP-3330. Available from: http://www.bloodjournal.org/content/106/9/3322.abstract
    OpenUrl
  26. 26.↵
    Busca A, Aversa F. In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation. Expert Opin Biol Ther [Internet]. 2017 Aug 28;17(11):1–15. Available from: https://doi.org/10.1080/14712598.2017.1369949
    OpenUrl
  27. 27.↵
    Beck R, Lam-Po-Tang PR. Comparison of cord blood and adult blood lymphocyte normal ranges: a possible explanation for decreased severity of graft versus host disease after cord blood transplantation. Immunol Cell Biol [Internet]. 1994 Oct;72(5):440–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7835989
    OpenUrl
  28. 28.
    D’Arena G, Musto P, Cascavilla N, Di Giorgio G, Fusilli S, Zendoli F, et al. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. Haematologica [Internet]. 1998 Mar;83(3):197–203. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9573672
    OpenUrl
  29. 29.↵
    Szabolcs P, Park K-D, Reese M, Marti L, Broadwater G, Kurtzberg J. Coexistent naïve phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. Exp Hematol [Internet]. 2003 Aug;31(8):708–14. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0301472X03001607
    OpenUrl
  30. 30.↵
    Rodrigues CA, Rocha V, Dreger P, Brunstein C, Sengeloev H, Finke J, et al. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica [Internet]. 2014 Feb 1;99(2):370 LP-377. Available from: http://www.haematologica.org/content/99/2/370.abstract
    OpenUrl
  31. 31.↵
    Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol [Internet]. 2010 Jul [cited 2018 Oct 20];11(7):653–60. Available from: www.thelancet.com/oncology
    OpenUrl
  32. 32.↵
    Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, DeFor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood [Internet]. 2010 Nov 25 [cited 2018 Oct 20];116(22):4693–9. Available from: www.bloodjournal.org
    OpenUrl
Back to top
PreviousNext
Posted June 12, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
CD56brightCD16- NATURAL KILLER CELLS ARE IN HIGHER COUNTS IN THE UMBILICAL CORD BLOOD THAN IN THE PERIPHERAL BLOOD
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
CD56brightCD16- NATURAL KILLER CELLS ARE IN HIGHER COUNTS IN THE UMBILICAL CORD BLOOD THAN IN THE PERIPHERAL BLOOD
Vinicius Campos de Molla, Míriam Cristina Rodrigues Barbosa, Alfredo Mendrone Junior, Matheus Vescovi Gonçalves, Eliza Kimura, Fabio Guirao, Mihoko Yamamoto, Celso Arrais-Rodrigues
medRxiv 2021.06.09.21258083; doi: https://doi.org/10.1101/2021.06.09.21258083
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
CD56brightCD16- NATURAL KILLER CELLS ARE IN HIGHER COUNTS IN THE UMBILICAL CORD BLOOD THAN IN THE PERIPHERAL BLOOD
Vinicius Campos de Molla, Míriam Cristina Rodrigues Barbosa, Alfredo Mendrone Junior, Matheus Vescovi Gonçalves, Eliza Kimura, Fabio Guirao, Mihoko Yamamoto, Celso Arrais-Rodrigues
medRxiv 2021.06.09.21258083; doi: https://doi.org/10.1101/2021.06.09.21258083

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Hematology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)